Cheng Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cheng Dong has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Yun Chang
Department of Biomedical Engineering, The Hong Kong Polytechnic University, 999077, Hong Kong, China
6 shared publications Bin Liu
Department of Biomedical Engineering, The Hong Kong Polytechnic University, 999077, Hong Kong, China
2 shared publications- Bin Liu
Department of Biomedical Engineering, The Hong Kong Polytechnic University, Kowloon, Hong Kong 999077, China
2 shared publications Tong Li
Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, China
2 shared publications- Xiaoping Bao
Davidson School of Chemical Engineering Purdue University West Lafayette Indiana USA
2 shared publications - Bingyang Dai
Department of Biomedical Engineering, Faculty of Engineering, The Hong Kong Polytechnic University, Hong Kong SAR, China
1 shared publication
Latest Publications
- Open Access
- 21 October 2026
- Published by Elsevier in SSRN Electronic Journal
Data-driven discovery of design principles of immunomodulatory hydrogels in arthritis treatment
Hydrogels are evolving from simple mechanical lubricants to active modulators of joint immunity in arthritis therapy. However, biomaterial development remains heavily constrained by empirical trial-and-error and a tendency to follow prevailing research trends. To challenge this dogma, we established a data-driven framework that bridges retrospective literature mining with prospective experimental validation. An interpretable machine learning (ML) model, trained on a comprehensive database of 220 hydrogel formulations from 317 published studies, was used to decode key design principles. The model identified the base polymer, functional agent, and elastic modulus as the most critical predictors of therapeutic efficacy, with immune profiling revealing that this therapeutic benefit is predominantly driven by anti-inflammatory M2 macrophage polarization. Crucially, while retrieval-augmented large language models inherited literature popularity bias by favoring trending polysaccharides, our ML framework and subsequent prospective assays prioritized protein-based matrices. Prospective experimental validation demonstrated that material composition outweighs mechanical properties, and that protein-based hydrogels induce stronger therapeutic M2 polarization than the currently trending polysaccharide-based alternatives. By challenging existing design assumptions, this work provides a generalizable strategy to transition biomaterials engineering from trend-following empirical testing to rational, data-driven discovery.
- 21 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessData-driven discovery of design principles of immunomodulatory hydrogels in arthritis treatment
Hydrogels are evolving from simple mechanical lubricants to active modulators of joint immunity in arthritis therapy. However, biomaterial development remains heavily constrained by empirical trial-and-error and a tendency to follow prevailing research trends. To challenge this dogma, we established a data-driven framework that bridges retrospective literature mining with prospective experimental validation. An interpretable machine learning (ML) model, trained on a comprehensive database of 220 hydrogel formulations from 317 published studies, was used to decode key design principles. The model identified the base polymer, functional agent, and elastic modulus as the most critical predictors of therapeutic efficacy, with immune profiling revealing that this therapeutic benefit is predominantly driven by anti-inflammatory M2 macrophage polarization. Crucially, while retrieval-augmented large language models inherited literature popularity bias by favoring trending polysaccharides, our ML framework and subsequent prospective assays prioritized protein-based matrices. Prospective experimental validation demonstrated that material composition outweighs mechanical properties, and that protein-based hydrogels induce stronger therapeutic M2 polarization than the currently trending polysaccharide-based alternatives. By challenging existing design assumptions, this work provides a generalizable strategy to transition biomaterials engineering from trend-following empirical testing to rational, data-driven discovery.
- 8 August 2026
- Published by Springer Nature in Cellular and Molecular Bioengineering
- Vol. 19 (4) , 549-565
Kindlin-3 is a Regulator of Force-Regulated Activation of Integrin α4β7 by CCL25 During Lymphocyte Adhesion
- 8 August 2026
- Published by Springer Nature in Cellular and Molecular Bioengineering
- Vol. 19 (4) , 549-565
Kindlin-3 is a Regulator of Force-Regulated Activation of Integrin α4β7 by CCL25 During Lymphocyte Adhesion
- Open Access
- 14 February 2026
- Published by Elsevier in Biomaterials
- Vol. 330, 124063
Macrophages: Redefining extracellular matrix architecture through phenotypic switches as therapeutic targets
- 14 February 2026
- Published by Elsevier in Biomaterials
- Vol. 330, 124063
Open AccessMacrophages: Redefining extracellular matrix architecture through phenotypic switches as therapeutic targets
- 1 January 2026
- Published by Higher Education Press in Advanced Clinical Engineering
- Vol. 1 (2) , 80
Inhalable Living Biotherapeutics and Bio-Derived Organisms for Precision Theranostics of Lung Diseases
Pulmonary delivery offers a noninvasive route for localized and systemic therapy while reducing gastrointestinal degradation and first-pass metabolism. However, its clinical efficacy is limited by heterogeneous pulmonary deposition, mucus and mucociliary clearance, macrophage-mediated elimination, disease-associated microenvironmental remodeling, and instability of biological cargoes during formulation and aerosolization. These challenges have driven growing interest in living biotherapeutics and bio-derived systems. These systems provide intrinsic capabilities for environmental sensing, tissue interaction, cellular targeting, cargo protection, and, in selected cases, active migration within diseased tissues. This narrative review presents an overview of inhaled living biotherapeutics and bio-derived carriers for precision theranostics of lung diseases, encompassing bacteria, bacteriophages, microalgae, mammalian cells, extracellular vesicles (EVs), outer membrane vesicles (OMVs), cell membrane-derived vesicles, and related biological systems. We classify these platforms by biological identity, mechanism of action, and product configuration, highlighting how intrinsic properties govern pulmonary distribution, target recognition, therapeutic activity, and safety. We further examine four engineering strategies: biological reprogramming, cargo loading and biointerface engineering, formulation and preservation, and aerosol delivery engineering. Finally, we discuss challenges in immunogenicity, phenotypic stability, dose consistency, scalability, aerosolization damage, and regulatory translation, outlining considerations for reproducible potency, safety, and quality. Collectively, these advances may transform passive pulmonary deposition into adaptive, mechanism-guided precision theranostics.
- 1 January 2026
- Published by Higher Education Press in Advanced Clinical Engineering
- Vol. 1 (2) , 80
Inhalable Living Biotherapeutics and Bio-Derived Organisms for Precision Theranostics of Lung Diseases
Pulmonary delivery offers a noninvasive route for localized and systemic therapy while reducing gastrointestinal degradation and first-pass metabolism. However, its clinical efficacy is limited by heterogeneous pulmonary deposition, mucus and mucociliary clearance, macrophage-mediated elimination, disease-associated microenvironmental remodeling, and instability of biological cargoes during formulation and aerosolization. These challenges have driven growing interest in living biotherapeutics and bio-derived systems. These systems provide intrinsic capabilities for environmental sensing, tissue interaction, cellular targeting, cargo protection, and, in selected cases, active migration within diseased tissues. This narrative review presents an overview of inhaled living biotherapeutics and bio-derived carriers for precision theranostics of lung diseases, encompassing bacteria, bacteriophages, microalgae, mammalian cells, extracellular vesicles (EVs), outer membrane vesicles (OMVs), cell membrane-derived vesicles, and related biological systems. We classify these platforms by biological identity, mechanism of action, and product configuration, highlighting how intrinsic properties govern pulmonary distribution, target recognition, therapeutic activity, and safety. We further examine four engineering strategies: biological reprogramming, cargo loading and biointerface engineering, formulation and preservation, and aerosol delivery engineering. Finally, we discuss challenges in immunogenicity, phenotypic stability, dose consistency, scalability, aerosolization damage, and regulatory translation, outlining considerations for reproducible potency, safety, and quality. Collectively, these advances may transform passive pulmonary deposition into adaptive, mechanism-guided precision theranostics.
- Open Access
- 27 October 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1166
Hematopoietic Stem Cell Aging: Mechanisms, Microenvironment Influences, and Rejuvenation Strategies
Hematopoietic stem cells (HSCs) are essential for lifelong blood production and immune homeostasis. However, aging induces functional declines in HSCs, leading to hematological disorders, immune dysfunction, and increased susceptibility to malignancies. This review explores the biological underpinnings of HSC aging, highlighting the intrinsic and extrinsic factors that drive this process. We discuss the molecular and cellular mechanisms contributing to HSC aging, including genetic instability, epigenetic alterations, metabolic shifts, and inflammation signaling. Additionally, we examine the role of the bone marrow microenvironment in modulating HSC aging, emphasizing the impact of niche interactions, stromal cell dysfunction, and extracellular matrix remodeling. To advance our understanding of HSC aging, pluripotent stem cell differentiation platforms provide a valuable tool for modeling aged HSC phenotypes and identifying potential therapeutic targets. We review current strategies for HSC rejuvenation, including metabolic reprogramming, epigenetic modifications, pharmacological interventions, and niche-targeted approaches, aiming to restore HSC function and improve regenerative potential. Finally, we present emerging perspectives on the clinical implications of HSC aging, discussing potential translational strategies for combating age-associated hematopoietic decline. By integrating insights from stem cell biology, aging research, and regenerative medicine, this review provides a comprehensive overview of HSC aging and its therapeutic potential. Addressing these challenges will be critical for developing interventions that promote hematopoietic health and improve outcomes in aging populations.
- 27 October 2025
- Published by MDPI AG in Bioengineering
- Vol. 12 (11) , 1166
Open AccessHematopoietic Stem Cell Aging: Mechanisms, Microenvironment Influences, and Rejuvenation Strategies
Hematopoietic stem cells (HSCs) are essential for lifelong blood production and immune homeostasis. However, aging induces functional declines in HSCs, leading to hematological disorders, immune dysfunction, and increased susceptibility to malignancies. This review explores the biological underpinnings of HSC aging, highlighting the intrinsic and extrinsic factors that drive this process. We discuss the molecular and cellular mechanisms contributing to HSC aging, including genetic instability, epigenetic alterations, metabolic shifts, and inflammation signaling. Additionally, we examine the role of the bone marrow microenvironment in modulating HSC aging, emphasizing the impact of niche interactions, stromal cell dysfunction, and extracellular matrix remodeling. To advance our understanding of HSC aging, pluripotent stem cell differentiation platforms provide a valuable tool for modeling aged HSC phenotypes and identifying potential therapeutic targets. We review current strategies for HSC rejuvenation, including metabolic reprogramming, epigenetic modifications, pharmacological interventions, and niche-targeted approaches, aiming to restore HSC function and improve regenerative potential. Finally, we present emerging perspectives on the clinical implications of HSC aging, discussing potential translational strategies for combating age-associated hematopoietic decline. By integrating insights from stem cell biology, aging research, and regenerative medicine, this review provides a comprehensive overview of HSC aging and its therapeutic potential. Addressing these challenges will be critical for developing interventions that promote hematopoietic health and improve outcomes in aging populations.
- Open Access
- 1 October 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 52, 529-540
Novel strategy for tumor immunotherapy using FITC-folate bispecific adapter bridged CAR immune cell cocktails
Adoptive immune cell-based therapies have shown promise in cancer treatment, yet their efficacy against solid tumors is often limited by the immunosuppressive tumor microenvironment (TME). To overcome these barriers, we design an innovative immune cell cocktail as a combinatorial biomaterial platform, which harnessing the complementary functions of neutrophils and natural killer (NK) cells derived from human pluripotent stem cells (hPSCs). Using CRISPR/Cas9, we introduce an anti-fluorescein isothiocyanate (FITC) chimeric antigen receptor (CAR) construct into the AAVS1 safe harbor locus of hPSCs, allowing for the differentiation of CAR-modified neutrophils and NK cells. These CAR neutrophils exhibit robust anti-tumor activity, forming immune synapses with tumor cells tagged via a bispecific adapter (FITC-folate), even in hypoxic TMEs, while CAR NK cells demonstrate antigen-specific cytotoxicity. Together, the cocktail biomaterial composed of CAR neutrophils and CAR NK cells creates a synergistic anti-tumor effect: having neutrophils enhance TME modulation, and NK cells provide targeted cytotoxicity. This biomaterial offers a scalable and off-the-shelf solution for producing CAR neutrophils and CAR NK cells, potentially reducing needs for high-dose exogenous cytokines and minimizing immune-related toxicities. Our findings suggest that hPSC-derived CAR neutrophils and CAR NK cells may form an effective immuno-cocktail biomaterial, offering a feasible strategy for advancing solid tumor immunotherapy through cellular synergy and TME adaptation.
- 1 October 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 52, 529-540
Open AccessNovel strategy for tumor immunotherapy using FITC-folate bispecific adapter bridged CAR immune cell cocktails
Adoptive immune cell-based therapies have shown promise in cancer treatment, yet their efficacy against solid tumors is often limited by the immunosuppressive tumor microenvironment (TME). To overcome these barriers, we design an innovative immune cell cocktail as a combinatorial biomaterial platform, which harnessing the complementary functions of neutrophils and natural killer (NK) cells derived from human pluripotent stem cells (hPSCs). Using CRISPR/Cas9, we introduce an anti-fluorescein isothiocyanate (FITC) chimeric antigen receptor (CAR) construct into the AAVS1 safe harbor locus of hPSCs, allowing for the differentiation of CAR-modified neutrophils and NK cells. These CAR neutrophils exhibit robust anti-tumor activity, forming immune synapses with tumor cells tagged via a bispecific adapter (FITC-folate), even in hypoxic TMEs, while CAR NK cells demonstrate antigen-specific cytotoxicity. Together, the cocktail biomaterial composed of CAR neutrophils and CAR NK cells creates a synergistic anti-tumor effect: having neutrophils enhance TME modulation, and NK cells provide targeted cytotoxicity. This biomaterial offers a scalable and off-the-shelf solution for producing CAR neutrophils and CAR NK cells, potentially reducing needs for high-dose exogenous cytokines and minimizing immune-related toxicities. Our findings suggest that hPSC-derived CAR neutrophils and CAR NK cells may form an effective immuno-cocktail biomaterial, offering a feasible strategy for advancing solid tumor immunotherapy through cellular synergy and TME adaptation.
- 19 July 2025
- Published by Springer Nature
- p. 305-341
Cell Membrane Engineering for Advancing Cancer Immunotherapy
- 19 July 2025
- Published by Springer Nature
- p. 305-341
Cell Membrane Engineering for Advancing Cancer Immunotherapy
- Open Access
Induced Pluripotent Stem Cells-Based Regenerative Therapies in Treating Human Aging-Related Functional Decline and Diseases
A significant increase in life expectancy worldwide has resulted in a growing aging population, accompanied by a rise in aging-related diseases that pose substantial societal, economic, and medical challenges. This trend has prompted extensive efforts within many scientific and medical communities to develop and enhance therapies aimed at delaying aging processes, mitigating aging-related functional decline, and addressing aging-associated diseases to extend health span. Research in aging biology has focused on unraveling various biochemical and genetic pathways contributing to aging-related changes, including genomic instability, telomere shortening, and cellular senescence. The advent of induced pluripotent stem cells (iPSCs), derived through reprogramming human somatic cells, has revolutionized disease modeling and understanding in humans by addressing the limitations of conventional animal models and primary human cells. iPSCs offer significant advantages over other pluripotent stem cells, such as embryonic stem cells, as they can be obtained without the need for embryo destruction and are not restricted by the availability of healthy donors or patients. These attributes position iPSC technology as a promising avenue for modeling and deciphering mechanisms that underlie aging and associated diseases, as well as for studying drug effects. Moreover, iPSCs exhibit remarkable versatility in differentiating into diverse cell types, making them a promising tool for personalized regenerative therapies aimed at replacing aged or damaged cells with healthy, functional equivalents. This review explores the breadth of research in iPSC-based regenerative therapies and their potential applications in addressing a spectrum of aging-related conditions.
Open AccessInduced Pluripotent Stem Cells-Based Regenerative Therapies in Treating Human Aging-Related Functional Decline and Diseases
A significant increase in life expectancy worldwide has resulted in a growing aging population, accompanied by a rise in aging-related diseases that pose substantial societal, economic, and medical challenges. This trend has prompted extensive efforts within many scientific and medical communities to develop and enhance therapies aimed at delaying aging processes, mitigating aging-related functional decline, and addressing aging-associated diseases to extend health span. Research in aging biology has focused on unraveling various biochemical and genetic pathways contributing to aging-related changes, including genomic instability, telomere shortening, and cellular senescence. The advent of induced pluripotent stem cells (iPSCs), derived through reprogramming human somatic cells, has revolutionized disease modeling and understanding in humans by addressing the limitations of conventional animal models and primary human cells. iPSCs offer significant advantages over other pluripotent stem cells, such as embryonic stem cells, as they can be obtained without the need for embryo destruction and are not restricted by the availability of healthy donors or patients. These attributes position iPSC technology as a promising avenue for modeling and deciphering mechanisms that underlie aging and associated diseases, as well as for studying drug effects. Moreover, iPSCs exhibit remarkable versatility in differentiating into diverse cell types, making them a promising tool for personalized regenerative therapies aimed at replacing aged or damaged cells with healthy, functional equivalents. This review explores the breadth of research in iPSC-based regenerative therapies and their potential applications in addressing a spectrum of aging-related conditions.
- Open Access
- 3 February 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-11
Forward programming of hPSCs to neutrophils using chemically defined media
Polymorphonuclear neutrophils (PMNs), the most abundant leukocytes circulating in human blood, are pivotal players in the innate immune system. In recent years, PMNs have gained increasing recognition for their significant involvement in the pathogenesis of a wide array of human diseases, including sepsis, pulmonary conditions, autoimmune disorders, and various cancers. Due to their terminally differentiated state, PMNs possess a short lifespan and exhibit limited proliferative potential, which makes continuous replenishment from the bone marrow essential for maintaining immune homeostasis. This demand underscores the need for efficient, reliable, and robust methods of PMN production. In this study, we evaluated three forward programming protocols and one directed differentiation protocol aimed at generating PMNs from human pluripotent stem cells (hPSCs). We analyzed not only their differentiation efficiency but also the transcriptomic profiles and functional capabilities of the resulting PMNs. Our findings revealed that both the forward programming method and the directed differentiation approach can successfully generate functional PMNs. Furthermore, by fine-tuning the culture media at various stages during forward programming, we identified an optimal protocol that significantly enhances hematopoietic differentiation potential and promotes the functional maturity of the neutrophils.
- 3 February 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-11
Open AccessForward programming of hPSCs to neutrophils using chemically defined media
Polymorphonuclear neutrophils (PMNs), the most abundant leukocytes circulating in human blood, are pivotal players in the innate immune system. In recent years, PMNs have gained increasing recognition for their significant involvement in the pathogenesis of a wide array of human diseases, including sepsis, pulmonary conditions, autoimmune disorders, and various cancers. Due to their terminally differentiated state, PMNs possess a short lifespan and exhibit limited proliferative potential, which makes continuous replenishment from the bone marrow essential for maintaining immune homeostasis. This demand underscores the need for efficient, reliable, and robust methods of PMN production. In this study, we evaluated three forward programming protocols and one directed differentiation protocol aimed at generating PMNs from human pluripotent stem cells (hPSCs). We analyzed not only their differentiation efficiency but also the transcriptomic profiles and functional capabilities of the resulting PMNs. Our findings revealed that both the forward programming method and the directed differentiation approach can successfully generate functional PMNs. Furthermore, by fine-tuning the culture media at various stages during forward programming, we identified an optimal protocol that significantly enhances hematopoietic differentiation potential and promotes the functional maturity of the neutrophils.
- Open Access
- 1 December 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 42, 379-403
Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has obtained Food and Drug Administration (FDA) approval as a treatment for various hematological malignancies, demonstrating promising preclinical efficacy against cancers. However, the intricate and resource-intensive autologous cell processing, encompassing collection, expansion, engineering, isolation, and administration, hamper the efficacy of this therapeutic modality. Furthermore, conventional CAR T therapy is presently confined to addressing solid tumors due to impediments posed by physical barriers, the potential for cytokine release syndrome, and cellular exhaustion induced by the immunosuppressive and heterogeneous tumor microenvironment. Consequently, a strategic integration of adoptive immunotherapy with synergistic multimodal treatments, such as chemotherapy, radiotherapy, and vaccine therapy etc., emerges as a pivotal approach to surmount these inherent challenges. This collaborative strategy holds the key to addressing the limitations delineated above, thereby facilitating the realization of more precise personalized therapies characterized by heightened therapeutic efficacy. Such synergistic strategy not only serves to mitigate the constraints associated with adoptive immunotherapy but also fosters enhanced clinical applicability, thereby advancing the frontiers of therapeutic precision and effectiveness.
- 1 December 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 42, 379-403
Open AccessAdvancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment
Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has obtained Food and Drug Administration (FDA) approval as a treatment for various hematological malignancies, demonstrating promising preclinical efficacy against cancers. However, the intricate and resource-intensive autologous cell processing, encompassing collection, expansion, engineering, isolation, and administration, hamper the efficacy of this therapeutic modality. Furthermore, conventional CAR T therapy is presently confined to addressing solid tumors due to impediments posed by physical barriers, the potential for cytokine release syndrome, and cellular exhaustion induced by the immunosuppressive and heterogeneous tumor microenvironment. Consequently, a strategic integration of adoptive immunotherapy with synergistic multimodal treatments, such as chemotherapy, radiotherapy, and vaccine therapy etc., emerges as a pivotal approach to surmount these inherent challenges. This collaborative strategy holds the key to addressing the limitations delineated above, thereby facilitating the realization of more precise personalized therapies characterized by heightened therapeutic efficacy. Such synergistic strategy not only serves to mitigate the constraints associated with adoptive immunotherapy but also fosters enhanced clinical applicability, thereby advancing the frontiers of therapeutic precision and effectiveness.